MTOR and autosomal dominant polycystic kidney disease: On the contrary, patients suffering from conditions such as TSC may need mTOR inhibitor treatment,40 which conversely was not shown to be beneficial in ADPKD.41 As TSC and BHDS represent tumor syndromes, disease recognition is crucial for affected families, prompting intrafamilial screening for malignancies and leading to differential transplant management with mTOR inhibitors as part of immunosuppressive regimens for those with ESRD.42